Home  |  Contact

Cellosaurus Kasumi-1 (CVCL_0589)

Cell line name Kasumi-1
Synonyms KASUMI-1; Kasumi 1; KASUMI1; Kasumi1
Accession CVCL_0589
Resource Identification Initiative To cite this cell line use: Kasumi-1 (RRID:CVCL_0589)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Population: Japanese.
Doubling time: 40-45 hours (PubMed=2018839); 40 hours (PubMed=25984343); 53 hours (PubMed=20922763); ~48-72 hours (DSMZ=ACC-220).
Karyotypic information: Has lost chromosome Y (PubMed=2018839).
Karyotypic information: Some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: Kusami-1; Cosmic=1516633; Cosmic=1623636; Cosmic=2750859.
Misspelling: KUSAMI-1; Cosmic=2306211.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (PubMed=11753612; PubMed=15843827; PubMed=24976338; PubMed=25485619).
  • Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Heterozygous (PubMed=12111653; PubMed=18385756).
  • Mutation; HGNC; 9811; RAD21; Simple; p.Lys330Profs*6 (c.987insCCGG); Zygosity=Unspecified (PubMed=23955599).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*26:01,26:01
HLA-BB*40:06,40:06
HLA-CC*03:03,08:01

Source: DSMZCellDive=ACC-220
Class I
HLA-AA*26:02:01,26:01:01
HLA-BB*40:06:01,48:01:01
HLA-CC*03:03:01,08:01:01
Class II
HLA-DPDPB1*02:01:02,02:01:02
HLA-DRDRA*01:01:01,01:01:01
DRB1*14:54:01,09:01:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.19
Native American0
East Asian, North74.84
East Asian, South22.29
South Asian0
European, North0
European, South1.67
Disease Childhood acute myeloid leukemia with maturation (NCIt: C9381)
Acute myeloblastic leukemia with maturation (ORDO: Orphanet_98834)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_JY44 (Kasumi-1 R48)
Sex of cell Male
Age at sampling 7Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; Genomics_Center_BCF_Technion; JCRB; PubMed=20922763; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,12
D1S165614,16
D2S44111,14
D2S133819
D3S135815,17
D5S8189,11
D7S8208,11
D8S117913,14
D10S124813,15
D12S39120
D13S31711,13
D16S5399,12
D18S5115,16
D19S43313,15.2 (COG; Genomics_Center_BCF_Technion; PubMed=20922763)
13,16 (DSMZ)
D21S1130,31
D22S104517
FGA22,24
Penta D12
Penta E11
TH016,9
TPOX8,9
vWA14 (ATCC; CLS; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; JCRB; PubMed=20922763; PubMed=25877200)
14,18 (COG)

Run an STR similarity search on this cell line
Web pages http://www.cccells.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
https://tcpaportal.org/mclp/
Publications

PubMed=2018839; DOI=10.1182/blood.V77.9.2031.2031
Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N.
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Blood 77:2031-2036(1991)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=11753612; DOI=10.1038/sj.leu.2402318
Xiao Z., Greaves M.F., Buffler P., Smith M.T., Segal M.R., Dicks B.M., Wiencke J.K., Wiemels J.L.
Molecular characterization of genomic AML1-ETO fusions in childhood leukemia.
Leukemia 15:1906-1913(2001)

PubMed=12111653; DOI=10.1038/sj.thj.6200168
Beghini A., Magnani I., Ripamonti C.B., Larizza L.
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
Hematol. J. 3:157-163(2002)

PubMed=15621809; DOI=10.1080/10428190400007565
Larizza L., Magnani I., Beghini A.
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Leuk. Lymphoma 46:247-255(2005)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T.J., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=18292219; DOI=10.1101/gr.068304.107
Chen J., Kim Y.C., Jung Y.-C., Xuan Z.-Y., Dworkin G., Zhang Y.-M., Zhang M.Q., Wang S.M.
Scanning the human genome at kilobase resolution.
Genome Res. 18:751-762(2008)

PubMed=18385756; DOI=10.1038/leu.2008.61
Becker H., Pfeifer D., Afonso J.D., Nimer S.D., Veelken H., Schwabe M., Lubbert M.
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
Leukemia 22:1792-1794(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20227111; DOI=10.1016/j.leukres.2010.02.012
Pedranzini L., Mottadelli F., Ronzoni S., Rossella F., Ferracin M., Magnani I., Roversi G., Colapietro P., Negrini M., Pelicci P.G., Larizza L.
Differential cytogenomics and miRNA signature of the acute myeloid leukaemia Kasumi-1 cell line CD34+38- compartment.
Leuk. Res. 34:1287-1295(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23955599; DOI=10.1038/ng.2731
Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat. Genet. 45:1232-1237(2013)

PubMed=24211243; DOI=10.1016/j.exphem.2013.10.006
Herrmann M.D., Lennerz J.K., Bullinger L., Bartholomae S., Holzmann K., Westhoff M.-A., Corbacioglu S., Debatin K.-M.
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Exp. Hematol. 42:90-100(2014)

PubMed=24976338; DOI=10.1016/j.leukres.2014.06.002
Migas A.A., Mishkova O.A., Ramanouskaya T.V., Ilyushonak I.M., Aleinikova O.V., Grinev V.V.
RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.
Leuk. Res. 38:1102-1110(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28109323; DOI=10.1186/s13045-017-0396-0
Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A., Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M., Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
J. Hematol. Oncol. 10:26.1-26.5(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29491412; DOI=10.1038/s41388-018-0150-2
Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D., Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N., Gerstberger T., Zuber J., Savarese F., Kraut N.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene 37:2687-2701(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32180206; DOI=10.1007/s13577-020-00347-5
Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M., Kohara A., Kaneko Y., Kawamura M.
Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.
Hum. Cell 33:868-876(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2724
BCRC; 60505
BCRJ; 0305
CCTCC; GDC0296
CLS; 300226
DSMZ; ACC-220
IZSLER; BS TCL 242
JCRB; JCRB1003
JCRB; NIHS0235 - Discontinued
Cell line databases/resources CLO; CLO_0007068
CLO; CLO_0007069
MCCL; MCC:0000264
CLDB; cl2998
cancercelllines; CVCL_0589
CCRID; 3101HUMSCSP5015
CCRID; 3101HUMTCHu202
CCRID; 4201HUM-CCTCC00296
Cell_Model_Passport; SIDM01005
Cosmic-CLP; 907275
DepMap; ACH-000263
DSMZCellDive; ACC-220
LINCS_LDP; LCL-1055
Anatomy/cell type resources BTO; BTO:0004136
Biological sample resources BioSample; SAMN01821572
BioSample; SAMN01821642
BioSample; SAMN01821688
BioSample; SAMN03473161
BioSample; SAMN10988020
CRISP screens repositories BioGRID_ORCS_Cell_line; 1617
Chemistry resources ChEMBL-Cells; CHEMBL3307835
ChEMBL-Targets; CHEMBL613988
GDSC; 907275
PharmacoDB; KASUMI1_733_2019
PubChem_Cell_line; CVCL_0589
Encyclopedic resources Wikidata; Q38098914
Experimental variables resources EFO; EFO_0006607
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM236785
GEO; GSM236821
GEO; GSM482490
GEO; GSM506744
GEO; GSM506867
GEO; GSM506973
GEO; GSM743409
GEO; GSM887197
GEO; GSM888270
GEO; GSM955189
GEO; GSM955190
GEO; GSM955191
GEO; GSM1374590
GEO; GSM1446745
GEO; GSM1669979
GEO; GSM2716744
GEO; GSM2716745
GEO; GSM2716746
GEO; GSM2716747
GEO; GSM4254129
Polymorphism and mutation databases Cosmic; 787441
Cosmic; 907275
Cosmic; 975258
Cosmic; 981579
Cosmic; 987968
Cosmic; 1012076
Cosmic; 1078725
Cosmic; 1149336
Cosmic; 1181600
Cosmic; 1451847
Cosmic; 1476423
Cosmic; 1509202
Cosmic; 1516633
Cosmic; 1524831
Cosmic; 1623636
Cosmic; 1779131
Cosmic; 2089650
Cosmic; 2131540
Cosmic; 2306211
Cosmic; 2690663
Cosmic; 2701742
Cosmic; 2750859
IARC_TP53; 21428
LiGeA; CCLE_291
Progenetix; CVCL_0589
Proteomic databases PRIDE; PXD000185
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number47